Breadcrumb navigation

PublicationsPublications

Publications

Explore our latest technological advancements and discover NEC Bio's innovative approach to AI-driven drug development.

Featured Publication

ESMO2024: Oral DNA vaccination targeting personalised neoantigens in immune checkpoint inhibitor treated solid tumor patients - Interim results.

  • Poster Number: 160P
  • Authors: Domas Vaitiekus, E. Juozaityte, L. PuzauskienÄ—, S. Tulyte, L. Gatijatullin, M. Platten, I. Poschke, I.Hulsmeyer, A. Kuhn, A. Aranguren, H. Lubenau, H. Fontenelle, B. Simovski, Y. Yamashita, C.Chaput, A. Meiser, V. Urbonas

poster

SITC2024: Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)

  • Poster Number: 650
  • Authors: Christophe Le Tourneau, Jean-Pierre Delord, Ana Lalanne, Camille Jamet, Clementine Spring-Giusti, Annette Tavernaro, Berangere Bastien, Maud Brandely-Talbot, Eric Quemeneur, Kousuke Onoue, Yoshiko Yamashita, Naoko Yamagata, Kazuhide Onoguchi, Ivy Grace Pait, Brandon Malone, Oliver Baker, Per Ludvik Brattas, Olivier Lantz, Kaidre Bendjama, Christian Ottensmeier

poster

SITC2024: Design of Enhanced TCRs Against Cancer Antigens Using an AI System

  • Poster Number: 1230
  • Authors: Martin Renqiang Min, Tianxiao Li, Kazuhide Onoguchi, Daiki Mori, Jonathan Warrell, Pierre Machart, Anja Moesch, Andrea Meiser, Ivy Grace Pait, Ayako Okamura, Daisuke Muraoka, Hirokazu Matsushita, Kaidre Bendjama

poster

White Paper

-Towards the realization of AI drug development-
Comprehensive process workflow for the commercial use of personalized cancer vaccines

NEC is committed to taking on the challenge of realizing new cancer treatments by aiming to establish an accurate, reliable, and comprehensive process workflow that utilizes AI and security technologies.

Outline

  1. A comprehensive process workflow that can be applied to a wide range of processes
  2. Important perspectives for consideration in the workflow
  3. Advanced technologies that will contribute to the realization of the workflow

 

poster

Publications / Presentations

Apr 3, 2024

K Bendjama, "AI Empowered Infectious Disease Vaccine Development" 2024; The World Vaccine Congress Washington

Mar 29, 2024

K Bendjama, "Towards realization of AI drug development:Comprehensive process workflow for the Commercial Use of Personalized Cancer Vaccines" 2024; NextGen Therapies Industry Working Group Summit

Jul 27, 2023

Y Yamashita, "Utilization of Artificial Intelligence in vaccine development." 2023; The 39th Annual Meeting of the Japan Society of Drug Delivery System

May 24, 2023

A Kitamura, "NEC's AI Drug Development Initiatives." 2023; 72nd SPSJ Annual Meeting

Jul 23, 2021

Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 57th Annual Meeting of Liver Cancer Study Group of Japan

Jun 19, 2021

Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 13th Annual Meeting of Japanese Society of Immunotherapy for Hematological Disorders

May 23, 2021

Y Yamashita, K Bendjama, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 18th Annual Meeting of Japan Research Association for Immunotherapeutics

Apr 16, 2021

Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; Bring Innovation in the Pharmaceutical Industry

Mar 5, 2021

Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2021; The 4th Social Smart Dental Hospital Symposium

Nov 29, 2019

Y Yamashita, "AI-based Neoantigen Prediction for Personalized Cancer Vaccine." 2019; The 32nd Annual Meeting of the Japan Society for Biological Therapy

Aug 23, 2019

K Onoue, Y Yamashita, B Malone, Y Tanaka, B Grellier, K Bendjama, K Machida, and K Udaka, "Evaluation of HLA-peptide binding prediction method." 2019; The 23rd Annual Meeting of Japanese Association of Cancer Immunology

Read more

Related Research Papers

NEC Laboratories Europe

NEC Laboratories Europe

Digital Health is a rapidly growing business for the NEC Group. In the Biomedical AI group, we consider challenges from prevention through to diagnosis and treatment.

NEC Laboratories America

NEC Laboratories America

Machine learning is a key technology for data analytics and artificial intelligence. We have been at the forefront of developments areas like deep learning and support vector machines for over a decade.